Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma： a Multicenter, Randomized Controlled Trial

NCT07524452 is registered in ClinicalTrials.gov with Ming-Yuan Chen as lead sponsor.

NCT NCT07524452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07524452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma： a Multicenter, Randomized Controlled Trial
Lead sponsor
Ming-Yuan Chen
Phase
Phase 3
Overall status
Recruiting
Start date
February 6, 2026
Completion date
February 28, 2032
Enrollment
430 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced head and neck squamous cell carcinoma